Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- EchoNext, developed at NewYork-Presbyterian and Columbia University, is the first FDA-cleared AI tool that reads standard 12-lead ECGs to flag six types of structural heart disease. - In a head-to-head study, EchoNext identified 77% of structural heart problems versus 64% accuracy by cardiologists, and was trained on over 700,000 ECG-echocardiogram pairs. - Nature Medicine published the first peer-reviewed case where AI detection of undiagnosed heart failure by EchoNext led to a heart transplant. - Pathway Labs announced an $8.5 million seed round and a partnership with OpenEvidence to deploy the tool across a platform used by over 500,000 U.S. clinicians.
- A whole-genome sequencing-based classifier demonstrated superior performance compared to standard assays in predicting homologous recombination deficiency across multiple cancer types. - The algorithm detected HRD in 21% of breast cancers, 20% of pancreaticobiliary cancers, and 17% of gynecologic cancers, with 24% of cases occurring in patients without BRCA1/2 mutations. - The study identified additional genomic mechanisms including biallelic mutations in FANCF, XRCC2, and FANCC that contribute to HRD phenotype. - Initial testing showed the algorithm flagged false negative and false positive results from commercial methods that didn't match patient outcomes.
- Volta Medical's AI-guided cardiac ablation combined with pulmonary vein isolation demonstrated 88% freedom from atrial fibrillation at 12 months, compared to 70% with standard treatment alone. - The TAILORED-AF trial, published in Nature Medicine, marks the first large-scale demonstration of AI benefits in interventional cardiology, involving 370 patients across 26 centers in 5 countries. - The groundbreaking study offers new hope for persistent AF patients, who represent 70% of the global AF population, with significantly improved outcomes despite longer procedure times.
- A multicenter study reveals that specific KRAS mutations in pancreatic ductal adenocarcinoma (PDAC) correlate with different survival outcomes. - The KRAS-G12D mutation is associated with more aggressive cancer and poorer prognosis, while KRAS-G12V and KRAS-G12R mutations show better overall survival. - Researchers suggest routine molecular testing for all pancreatic cancer patients, including those with early-stage disease, to guide personalized treatment strategies. - The study highlights the potential for tailoring treatments like chemotherapy or radiation based on the specific KRAS mutation present in the tumor.
